


IMF PATIENT AND FAMILY WEBINAR



Brian G.M. Durie, MD

Rafat Abonour, MD

Paul Richardson, MD

Yelak Biru

Saturday, March 14th, 2020

Thank you to our sponsors!



TODAY'S SPEAKERS


Saturday
MARCH 14
2020

IMF PATIENT & FAMILY **WEBINAR**

Watch the **LIVESTREAM**: 8:00 AM PT/10:00 AM CT/11:00 AM ET



Brian G.M. Durie, MD
Cedars-Sinai Medical Center, Los Angeles, CA



Paul Richardson, MD
Dana-Farber Cancer Institute, Boston, MA



Rafat Abonour, MD
University of Indiana, Indianapolis, IN



Yelak Biru
Patient Advocate, NW Arkansas

TOPICS FOR DISCUSSION

- **Coronavirus: COVID-19**
- **Frontline therapy**
- **Maintenance**
- **Approaches to Relapse**
- **Novel Therapies**

Q&A after each topic

COVID-19



COVID-19

Symptoms of Concern

- Fever (90%)
- Dry Cough (70%)
- Extra Tiredness (30%)

Note: Cold/Flu Symptoms only 3%

COVID-19

Avoiding Exposure


- **Social Distancing:** Stay home for now
- Handwashing and don't touch your face
- Clean surfaces including phones and screens
- Monitor family, friends and all contacts
- Avoid doctor's offices, hospitals and large clinics
- Have a plan of action when symptoms emerge

COVID-19

Q&A

FRONTLINE THERAPY

Managing Myeloma: The Components



FRONTLINE THERAPY

- What is best?
- Are dara + triplet regimens the way forward?


Daratumumab +VTD Produces Deeper Responses



Post-consolidation (D 100 Post-ASCT) Response and MRD-negative Rates: ITT.

	D-VTd, %	VTd, %	OR (95% CI)	P
sCR	28.9	20.3	1.60 (1.21-2.12)	0.0010
≥CR	38.9	26.0	1.82 (1.40-2.36)	<0.0001
≥VGPR	83.4	78.0	1.41 (1.04-1.92)	0.0239
MRD-negative (10⁻⁵)	63.7	43.5	2.27 (1.78-2.90)	<0.0001
≥CR + MRD-negative (10⁻⁵)	33.7	19.9	2.06 (1.56-2.72)	<0.0001

MYELOMA: FRONTLINE TREATMENT



FRONTLINE THERAPY

Q&A

What are recommendations for maintenance?

MAINTENANCE


- Current Approaches
- Revlimid \pm Proteasome Inhibitor
- Modifying for side effects
- Stopping for intolerance and/or MRD +/-

MAINTENANCE

Q&A

What are current relapse options?

MYELOMA: FIRST RELAPSE



MYELOMA: SECOND OR HIGHER RELAPSE

First Relapse Options



- Any first relapse options that have not been tried

(2 new drugs;
triplet preferred)

Isa-Pd, or DPd, or DKd, or KPd
after approval

Additional Options



- VDT-PACE like anthracycline containing regimens
- Melphalan/**melflufen**
- Adding Panobinostat
- Quadruplet regimens
- CART
- Bispecific
- Conjugated BCMA
- **Selinexor**
- **Referral for clinical trials always if available**

APPROACHES TO RELAPSE

Q&A


NOVEL AGENTS OR COMBINATION AT RELAPSE

- dara/Kyprolis/dex (CANDOR): LBA-6
- dara/Pom/dex
- Kyprolis/Pom/dex
- iberdomide (CC-220)
- melflufen
- I ¹³¹ CLR 1404 (lipid rafts target)

IMMUNE THERAPY RESULTS DOMINATE ASH 2019

- **CAR T Therapy**
- **Bispecific T Cell Engagers**
- **MoAb/drug conjugate: GSK 2857916 (“belamaf”)**

TIME FOR A PAUSE TO CONSIDER 100% RESPONSES!




ASH Abstract #143: Anti-BCMA [2] T Cell Engager (TCE): Phase 1 Trial of CC 93249


Dose
Response



RESPONSE OVER TIME



- Median time to first response was 4.1 weeks (range 4.0–13.1)
- 5 of 30 (16.7%) patients achieved an MRD-negative sCR/CR
 - Of 13 responding patients, 92.3% achieved MRD negativity ($\leq 1/10^5$) in the bone marrow on or before C4D1 by Euroflow^a



Data as of October 28, 2019

^a MRD negativity by Euroflow analysis was reported only if a minimum sensitivity of ≤ 1 tumor cell in 10^5 nucleated cells was achieved and in patients who had ≤ 1 baseline and ≤ 1 post-baseline MRD assessment. HTB, high tumor burden (defined as $> 50\%$ bone marrow plasma cells or > 5 extramedullary lesions); LTB, low tumor burden (defined as $\leq 50\%$ bone marrow plasma cells and ≤ 5 extramedullary lesions); MR, minimal response.

Luciano J. Costa, MD, PhD, et. al.

ROLE OF IMMUNE THERAPIES

Clearly active in relapsed patient population

How should BCMA targeted therapy be used and sequenced?

Is earlier use the best approach?

- **For consolidation?**
- **At first relapse?**

2020 EXPECTATIONS

Potential New Approvals

- GSK
- bb 2121 CAR T
- Legend CAR T
- Melflufen

Longer Term Results

- Cassiopia
- Griffin
- Dar KRd
- CESAR/ASCENT F/u

New Agent Data

- I ¹³¹ CLR 140L
- Iberdomide
- Several others

NOVEL THERAPIES

Q&A

Thank you to our sponsors!



